<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation and treatment of acute cellular lung transplant rejection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation and treatment of acute cellular lung transplant rejection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation and treatment of acute cellular lung transplant rejection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Pilewski, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ramsey R Hachem, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute allograft rejection is a significant problem in lung transplantation. Despite advances in induction immunosuppression and use of aggressive maintenance immunosuppression, more than a third of lung transplant recipients are treated for acute rejection in the first year after transplant [
         <a href="#rid1">
          1-3
         </a>
         ]. Acute rejection is responsible for approximately 4 percent of deaths in the first 30 days following transplantation [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         The clinical manifestations, evaluation, and treatment of acute cellular lung transplant rejection and the role of routine monitoring for rejection will be reviewed here. The immunobiology of transplantation, induction and maintenance immunosuppression after lung transplantation, primary graft dysfunction, humoral rejection, and chronic lung transplant rejection are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">
          "Transplantation immunobiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4661.html" rel="external">
          "Induction immunosuppression following lung transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">
          "Primary lung graft dysfunction"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/128271.html" rel="external">
          "Chronic lung allograft dysfunction: Restrictive allograft syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5081209">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute cellular rejection
         </strong>
         – Acute cellular rejection is the predominant type of acute lung transplant rejection and is mediated by T lymphocyte recognition of foreign major histocompatibility complexes (MHC), also known as human leukocyte antigens (HLA) in humans, or other antigens [
         <a href="#rid1">
          1,4,5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Humoral rejection
         </strong>
         – Humoral rejection, which is less common than acute cellular rejection, is mediated by antibodies directed against donor HLA or other epitopes. These antibodies may have been present in the recipient at a low level prior to transplant or may develop afterwards. Generally, if HLA antibodies are identified in the potential recipient, the corresponding HLA antigens are avoided in a donor (so-called virtual cross-match).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperacute rejection
         </strong>
         – Hyperacute rejection is a form of humoral rejection that occurs in the first 24 hours following lung transplantation in recipients who have pre-formed anti-HLA antibodies. With improved sensitivity of HLA antibody testing, hyperacute rejection now rarely occurs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic lung allograft dysfunction
         </strong>
         – Chronic lung transplant rejection is manifest pathologically as dense fibrous scar tissue affecting the small airways. Clinically, chronic lung transplant rejection is known as chronic lung allograft dysfunction (CLAD), which manifests as persistent airway obstruction that is defined as a decline in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ). In addition, a form of restrictive CLAD (CLAD – restrictive allograft syndrome [RAS]) has been described and appears to have significant prognostic implications [
         <a href="#rid6">
          6
         </a>
         ]. Less commonly, chronic vascular rejection with atherosclerosis in the pulmonary vasculature is also present.
        </p>
        <p>
        </p>
        <p>
         Discussions of humoral lung transplant rejection, including hyperacute rejection, and chronic lung transplant rejection are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128271.html" rel="external">
          "Chronic lung allograft dysfunction: Restrictive allograft syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5081202">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our knowledge of the pathology of lung allograft rejection comes from both clinical and experimental observations [
         <a href="#rid7">
          7-12
         </a>
         ]. The histopathologic manifestation of acute cellular rejection is a lymphocyte-predominant inflammatory response centered on blood vessels and/or airways, the mechanism of which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">
          "Transplantation immunobiology"
         </a>
         .)
        </p>
        <p>
         The International Society for Heart and Lung Transplantation (ISHLT) has developed a "Working Formulation of the Standardization of the Nomenclature in the Diagnosis of Lung Rejection," which was revised in 2007  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13-15
         </a>
         ]. This schema classifies rejection according to the anatomic structures involved and the severity of the abnormality. The key histopathologic features of acute cellular rejection are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A vascular component consisting of perivascular mononuclear infiltrates that may extend to the subendothelium; this lymphocyte infiltration can spread to involve the alveolar walls in higher grades of rejection  (
         <a class="graphic graphic_picture graphicRef63730 graphicRef75560" href="/z/d/graphic/63730.html" rel="external">
          picture 1A-B
         </a>
         ). The specific alloantigens responsible for this vasocentric inflammatory response remain undefined. The grades range from A0 (no rejection) to A4 (severe).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An airway component with a lymphocytic response initially in the submucosa of bronchioles and with increasing severity extending through the basement membrane. Bronchiolar inflammation may occur either in isolation or simultaneously with vascular inflammation. Ulceration of the airway epithelium may occur in more advanced cases  (
         <a class="graphic graphic_picture graphicRef77118 graphicRef52040" href="/z/d/graphic/77118.html" rel="external">
          picture 2A-B
         </a>
         ). The grades range from B0 (no rejection) to B2R (high grade, revised 2007 system) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Occasional eosinophils may be present in the vascular and bronchiolar components of acute cellular rejection. The presence of hyaline fibrosis in airways and vessels remains the key histologic discriminator between acute and chronic rejection of the lung [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5079680">
         <span class="h1">
          RISK FACTORS FOR ACUTE REJECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of acute lung transplant rejection is greatest in the first few months after transplant and decreases with time. Several factors have been implicated as contributing to the development of acute cellular rejection. The potential factors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human leukocyte antigens (HLA) mismatching – An increasing degree of HLA mismatch between the donor and recipient increases the risk of acute cellular rejection [
         <a href="#rid2">
          2
         </a>
         ]. A multi-center observational study demonstrated a higher frequency of acute rejection in the first post-transplant year in patients with four or more HLA mismatches [
         <a href="#rid16">
          16
         </a>
         ]. However, mismatch at certain HLA loci may be more important than at others [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic factors – Genetic variants in interleukin (IL)-10, multidrug resistance genotype, CCL4L chemokine, and toll-like receptor 4(TLR4) may influence the risk of acute rejection [
         <a href="#rid18">
          18-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunosuppression regimen – In the International Society for Heart and Lung Transplantation (ISHLT) registry, the rate of acute rejection in the first year was highest among recipients on cyclosporine-based regimens and lowest among those on tacrolimus-based regimens [
         <a href="#rid22">
          22
         </a>
         ]. In addition, induction therapy with an interleukin-2R antagonist was associated with a lower rate of acute rejection than other induction regimens. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'Calcineurin inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4661.html" rel="external">
          "Induction immunosuppression following lung transplantation", section on 'Induction agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age – More rejection episodes were reported among recipients in the lowest age category (18 to 34 years) than in older age categories, although this data from the ISHLT registry was not adjusted for underlying disease or other potentially confounding factors [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vitamin D deficiency − In a cohort of 102 lung transplant recipients, episodes of acute cellular rejection were more frequent among those with deficiency (&lt;30 ng/mL) in 25-hydroxyvitamin D (25-OH D) near the time of transplantation, than among those with normal 25-OH D levels (incidence rate ratio 2.43, 95% CI 1.30 to 4.52) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute cellular rejection is most likely to occur in the first six months following lung transplantation [
         <a href="#rid25">
          25,26
         </a>
         ]. Often, patients are asymptomatic, and the diagnosis is made from surveillance transbronchial biopsies. When present, symptoms are nonspecific and are shared by other common complications that occur during this period. They include low-grade fever, shortness of breath, and cough with or without sputum production  (
         <a class="graphic graphic_table graphicRef54968" href="/z/d/graphic/54968.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,27
         </a>
         ].
        </p>
        <p>
         During long-term follow-up of 120 lung transplant recipients, shortness of breath and cough were more common in those with clinically significant acute rejection (grade ≥A2) than those without (grade A0 or A1)  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ), but comparable in frequency to those with pulmonary infection. For predicting grade &gt;A2 rejection, the sensitivity and specificity were 68 and 50 percent for cough and 63 and 68 percent for shortness of breath, respectively.
        </p>
        <p>
         Lung examination may reveal clear lung fields, crackles, or decreased breath sounds when a pleural effusion is present as part of the acute rejection. High grade rejection may be associated with respiratory distress [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H472881">
         <span class="h1">
          EVALUATION OF SYMPTOMATIC PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         When lung transplant recipients present with nonspecific respiratory symptoms, the differentiation between acute allograft rejection, airway stenosis, and infection requires a combination of pulmonary function testing, imaging, and bronchoscopy [
         <a href="#rid27">
          27
         </a>
         ]. As acute rejection requires intensification of immunosuppression, which could be deleterious in the presence of opportunistic infection, a definitive diagnosis is highly desirable. In most circumstances this can be achieved by a transbronchial biopsy.
        </p>
        <p class="headingAnchor" id="H435910">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing in patients with suspected acute lung transplant rejection is generally nonspecific. Peripheral eosinophilia may be present; however, specific blood markers for rejection are not available. As infection is in the differential diagnosis, microbiologic stains and cultures are obtained from sputum, and bronchoalveolar lavage or bronchial washing samples. Cytomegalovirus (CMV) viral load testing is performed on peripheral blood. (See
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients", section on 'Pneumonitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2367932906">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spirometry is typically obtained at routine follow-up visits following lung transplantation and if dyspnea develops or worsens. The typical pulmonary function test abnormalities in acute cellular lung transplant rejection are airflow obstruction manifest by a decrease in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) [
         <a href="#rid28">
          28
         </a>
         ], or restriction manifest by a reduction in both forced vital capacity (FVC) and FEV
         <sub>
          1
         </sub>
         . The sensitivity of a decrease in FEV
         <sub>
          1
         </sub>
         for detecting acute rejection is approximately 60 percent [
         <a href="#rid2">
          2,27,28
         </a>
         ]. Thus, stable pulmonary function as determined by spirometry does not exclude acute lung transplant rejection [
         <a href="#rid28">
          28
         </a>
         ]. Among lung transplant recipients, respiratory infection is associated with a similar decrease in FEV
         <sub>
          1
         </sub>
         , so spirometry does not differentiate between these entities [
         <a href="#rid28">
          28
         </a>
         ]. Bronchial stenosis is in the differential diagnosis of airflow limitation following lung transplantation and provides additional rationale for bronchoscopy to evaluate new respiratory symptoms or a decline in lung function.
        </p>
        <p>
         Limited data are available on changes in total lung capacity (TLC) and diffusing capacity (DLCO) in association with acute lung transplant rejection. Among heart-lung transplant recipients, acute rejection is associated with decreases in TLC and DLCO [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chest radiograph is typically obtained as part of routine assessment and to assess the cause of new onset of dyspnea or cough in lung transplant recipients. Its main role in this setting is to identify diseases other than acute rejection. In early episodes of rejection (within the first three months), the chest radiograph may demonstrate perihilar opacities and interstitial edema with or without a pleural effusion [
         <a href="#rid1">
          1
         </a>
         ]. However, the sensitivity and specificity of the chest radiograph are low [
         <a href="#rid1">
          1
         </a>
         ]. The chest film is unchanged in approximately 80 percent of later episodes of rejection [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
         High resolution computed tomography (HRCT) is often obtained to assess the severity and distribution of the disease process or to guide the bronchoscopist in choosing sites for bronchoalveolar lavage or transbronchial biopsy. HRCT findings of acute lung transplant rejection include ground glass opacities, septal thickening, volume loss, and pleural effusion [
         <a href="#rid1">
          1
         </a>
         ]. However, HRCT findings are neither sensitive nor specific and do not differentiate between infection and rejection [
         <a href="#rid1">
          1,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H348992">
         <span class="h2">
          Pleural fluid analysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pleural effusions are common in the first two weeks following lung transplantation and do not require fluid analysis unless the effusion is large or the patient has signs of infection. When a new onset pleural effusion is identified after the first couple of weeks, ultrasound guided thoracentesis is usually performed to obtain fluid for analysis and culture. Among patients with a pleural effusion associated with acute cellular lung transplant rejection, the pleural fluid is typically lymphocytic, although this finding is not specific. Chylothorax, another cause of lymphocytic effusions following lung transplantation, can develop due to disruption of the thoracic duct or as a complication of lymphangioleiomyomatosis. (See
         <a class="medical medical_review" href="/z/d/html/4653.html" rel="external">
          "Pleural complications in lung transplantation", section on 'Pleural effusions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4322117">
         <span class="h2">
          Flexible bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         When patients present with a clinical syndrome suggestive of rejection or infection, most centers perform bronchoscopy with bronchoalveolar lavage and transbronchial biopsy in an attempt to establish a specific diagnosis  (
         <a class="graphic graphic_table graphicRef72570" href="/z/d/graphic/72570.html" rel="external">
          table 3
         </a>
         ). The techniques of bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB) are discussed separately [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4398.html" rel="external">
          "Flexible bronchoscopy in adults: Overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106085.html" rel="external">
          "Flexible bronchoscopy in adults: Associated diagnostic and therapeutic procedures", section on 'Transbronchial biopsy'
         </a>
         .)
        </p>
        <p>
         Common clinical practice is to sample multiple segments of a single lung allograft. In patients with focal radiographic abnormalities, BAL and biopsies are concentrated in the area of the radiologic abnormality. Samples are sent for cell count and differential, microbiologic stains and cultures, cytology, and histopathology.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchoalveolar lavage
         </strong>
         ─ During the first three months following lung transplantation, total BAL cell counts are elevated, and a neutrophilic alveolitis (eg, 25 to 50 percent neutrophils) is common [
         <a href="#rid33">
          33
         </a>
         ]. In contrast, acute cellular rejection is associated with a lymphocytic alveolitis (eg, 10 to 60 percent lymphocytes) with a decreased CD4/CD8 ratio. However, these findings are nonspecific and lymphocytic alveolitis is also seen in viral pneumonias and obliterative bronchiolitis [
         <a href="#rid33">
          33
         </a>
         ]. Data is conflicting, but the degree of BAL lymphocytosis does not correlate well with the histologic grade of rejection [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transbronchial biopsy
         </strong>
         ─ When imaging studies suggest diffuse disease or are normal, transbronchial biopsies are typically obtained from the lower lobes; when disease is radiographically patchy, biopsies are obtained from diseased areas [
         <a href="#rid35">
          35
         </a>
         ]. Practices vary concerning the number of transbronchial biopsies obtained for adequate sampling. Animal studies suggest that three good transbronchial biopsies have a sensitivity of 92 percent in identifying moderate to severe rejection and five biopsies have a similar sensitivity in identifying mild rejection [
         <a href="#rid15">
          15,36
         </a>
         ]. Most centers try to obtain 6 to 10 biopsies in order to achieve 5 "adequate" or "good" specimens, defined as samples with at least five alveoli. The sensitivity of transbronchial biopsy for diagnosing acute rejection is 61 to 94 percent and the specificity greater than 90 percent with an experienced pulmonary pathologist [
         <a href="#rid37">
          37,38
         </a>
         ]. The sensitivity for the diagnosis of cytomegalovirus pneumonia is approximately 90 percent [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Generally, only one lung is biopsied during a single bronchoscopy in heart-lung or bilateral lung recipients. The major exception to this practice is in patients who have received bilateral living-donor lobar transplants. In these patients, the lower lobes come from two different donors, and rejection is typically limited to one of the donor lobes and is rarely bilateral. As a result, living-donor recipients with no localizing signs or radiographic abnormalities may need to have both lower lobes biopsied [
         <a href="#rid39">
          39
         </a>
         ]. Fluoroscopy can be used to document the absence of pneumothorax on the first side before proceeding to biopsy the contralateral side.
        </p>
        <p>
        </p>
        <p>
         Adverse events reported with flexible bronchoscopy in lung transplant recipients are infrequent and include transient hypoxemia (10 percent), bleeding greater than 100 mL (4 percent), postprocedure pneumonia (2 percent), pneumothorax (1 to 3 percent), and arrhythmia (1 to 4 percent) [
         <a href="#rid2">
          2,26,40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H58704371">
         <span class="h1">
          MONITORING ASYMPTOMATIC PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute cellular rejection of the lung allograft is a major risk factor for development of CLAD – bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS) [
         <a href="#rid42">
          42
         </a>
         ]. Thus, an important goal of monitoring for acute allograft rejection in asymptomatic patients is to reduce the likelihood of late complications by preemptive treatment of acute cellular rejection. The two main forms of monitoring are spirometry and transbronchial biopsy. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         .)
        </p>
        <p>
         The use of biomarkers to detect asymptomatic allograft dysfunction is an area of active research.
        </p>
        <p class="headingAnchor" id="H58704398">
         <span class="h2">
          Spirometry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Office spirometry is considered a critical tool for monitoring allograft function. However, the frequency of office spirometry and the use of home spirometry vary among transplant centers.
        </p>
        <p>
         Office spirometry is typically performed at the time of follow-up visits after lung transplantation. Once postoperative function has stabilized the variation in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and forced vital capacity (FVC) is less than 5 percent. Spirometry has been reported to have a sensitivity of 60 percent in detecting rejection (grade ≥A2) or infection among bilateral lung transplant recipients  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,43
         </a>
         ]. A decline of 10 percent in spirometric values that persists for more than two days has been reported to indicate either rejection or infection [
         <a href="#rid43">
          43-45
         </a>
         ]. In single lung transplant recipients, spirometry is less helpful as changes may reflect progression of the underlying disease in the native lung [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Performance of patient-administered home spirometry several times a week may lead to earlier detection of CLAD, but the effect on long-term outcomes is less clear [
         <a href="#rid47">
          47
         </a>
         ]. The potential benefit of frequent spirometry remains an area of active research.
        </p>
        <p class="headingAnchor" id="H58704405">
         <span class="h2">
          Surveillance bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of surveillance bronchoscopy with transbronchial biopsy remains controversial, and the performance of routine surveillance transbronchial biopsies varies between lung transplant centers [
         <a href="#rid40">
          40,48-50
         </a>
         ], but the majority of lung transplant programs perform surveillance bronchoscopy. The technique of transbronchial biopsy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4398.html" rel="external">
          "Flexible bronchoscopy in adults: Overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106085.html" rel="external">
          "Flexible bronchoscopy in adults: Associated diagnostic and therapeutic procedures", section on 'Transbronchial biopsy'
         </a>
         .)
        </p>
        <p>
         The rationale for surveillance biopsy protocols is based upon studies that show a substantial prevalence of pathologic evidence of rejection in asymptomatic patients. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retrospective evidence that up to 25 percent of surveillance transbronchial biopsies demonstrate evidence of allograft rejection [
         <a href="#rid40">
          40,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 121 surveillance bronchoscopies, acute rejection, grade 2 or higher, was noted in 16 percent [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 1770 bronchoscopies, lymphocytic bronchiolitis grade 1 or higher was noted in 14 percent [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retrospective analysis demonstrating that lymphocytic bronchiolitis (grade B acute rejection)  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ) is a risk factor for subsequent development of CLAD [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         However, a survival benefit of surveillance biopsies has not been demonstrated [
         <a href="#rid50">
          50
         </a>
         ]. A single-center, randomized trial of 47 recipients did not demonstrate any clinical benefit from surveillance biopsies [
         <a href="#rid41">
          41
         </a>
         ]. A separate retrospective study found that the presence of lymphocytic bronchiolitis, but not vascular rejection on transbronchial biopsy correlated with reduced survival [
         <a href="#rid42">
          42
         </a>
         ]. This observation raised the possibility that previous studies that failed to demonstrate a benefit to surveillance bronchoscopy were looking at the wrong pathologic feature (ie, acute vascular rejection rather than lymphocytic bronchiolitis). Further research is needed to determine whether early treatment of lymphocytic bronchiolitis based on surveillance bronchoscopy results reduces the risk of CLAD and improves survival.
        </p>
        <p>
         In a 2004 survey, approximately 69 percent of North American lung transplant centers performed surveillance transbronchial biopsies, although a wide variety of protocols was used [
         <a href="#rid48">
          48,51
         </a>
         ]. A representative surveillance biopsy schedule is: 1 month, 3 months, 6 months, 12 months, 18 months, and 24 months [
         <a href="#rid48">
          48
         </a>
         ]. Reports in the literature suggest a much lower yield after 24 months, and most centers do not routinely perform biopsies after this point. Some centers perform bronchoalveolar lavage (BAL) without transbronchial biopsy after the first year [
         <a href="#rid40">
          40
         </a>
         ]. Other centers use the history of rejection in the first four months to determine the frequency of surveillance biopsies at 6 months and beyond [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H58704412">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest imaging studies, including high resolution computed tomography (HRCT), have a low sensitivity (as low as 35 percent) for acute lung transplant rejection and are typically not used for screening [
         <a href="#rid1">
          1,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute cellular rejection in lung transplant recipients is based on the presence of characteristic histopathologic changes on transbronchial lung biopsy specimens  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ) and exclusion of infection [
         <a href="#rid15">
          15
         </a>
         ]. Transbronchial lung biopsies need to be interpreted by a pathologist with experience in lung transplantation. When the patient undergoes biopsy at a site other than a transplant center, it is common practice to send the biopsy slides to the transplant center for review. (See
         <a class="local">
          'Pathology'
         </a>
         above and
         <a class="local">
          'Flexible bronchoscopy'
         </a>
         above.)
        </p>
        <p>
         For symptomatic patients, additional support for a diagnosis of acute cellular rejection includes the absence of airway stenosis at the time of flexible bronchoscopy and confirmation of negative microbiologic assays, stains, and cultures. (See
         <a class="medical medical_review" href="/z/d/html/4662.html" rel="external">
          "Airway complications after lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
         Clinical assessment without transbronchial biopsy is frequently inaccurate, as noted in a study from an experienced center in which only a 54 percent concordance rate was found between the clinical impression and the final pathologic diagnosis. Transbronchial lung biopsies improve the yield for a specific diagnosis to approximately 70 percent. (See
         <a class="local">
          'Flexible bronchoscopy'
         </a>
         above.)
        </p>
        <p>
         If the transbronchial biopsy does not yield a specific diagnosis and the patient has progressive respiratory impairment, repeat transbronchial biopsy, a video-assisted thoracoscopic lung biopsy, or, in the setting of acute lung injury, empiric therapy may be needed.
        </p>
        <p class="headingAnchor" id="H5080629">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to acute cellular rejection, the differential diagnosis of a decline in allograft function after initial recovery includes infection, humoral rejection, airway complications (eg, stenosis at the bronchial anastomosis, airway malacia and granulation tissue), chronic rejection (chronic lung allograft dysfunction [CLAD ], thromboembolism, and recurrent primary disease [
         <a href="#rid52">
          52,53
         </a>
         ]. These alternate diagnoses are typically excluded by studies such as PCR (polymerase chain reaction) assays for cytomegalovirus, fiberoptic bronchoscopy to examine the airway, D-dimer assessment, extensive microbiologic stains and cultures of bronchoalveolar lavage specimens, and histopathologic examination of transbronchial biopsies. (See
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection", section on 'Diagnosis and differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4662.html" rel="external">
          "Airway complications after lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">
          "Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">
          "Noninfectious complications following lung transplantation", section on 'Recurrent primary disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">
          "Noninfectious complications following lung transplantation", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
         Features that suggest infection include the presence of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute inflammatory cells such as polymorphonuclear leukocytes in the bronchoalveolar lavage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predominantly alveolar inflammation rather than vascular or airway-centered inflammation on biopsy (see
         <a class="local">
          'Pathology'
         </a>
         above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral inclusions on cytology or transbronchial biopsy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of infectious pathogens on special stains or culture
        </p>
        <p>
        </p>
        <p>
         Infection and acute rejection can also occur together, and it can be difficult or impossible to make the diagnosis of acute rejection in the presence of viral infections (cytomegalovirus, metapneumovirus, adenovirus, and severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] in particular) because of the lymphocytic infiltrate that accompanies such infections. In the presence of active cytomegalovirus (CMV) infection, a common approach is to treat the infection and then repeat the biopsies to assess any contribution of rejection to the patient's clinical syndrome. The alternative of empirically treating possible acute cellular rejection by intensifying immunosuppression is avoided due to concern that it would impair clearance of the CMV infection. (See
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"
         </a>
         .)
        </p>
        <p>
         In addition, cellular and humoral rejection may occur concomitantly, and antibody-mediated rejection should be considered particularly in the setting of refractory acute cellular rejection. (See
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          TREATMENT OF ACUTE CELLULAR REJECTION
         </span>
        </p>
        <p class="headingAnchor" id="H58704759">
         <span class="h2">
          Deciding when to treat
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to treat patients with histologic evidence of acute cellular rejection is based upon the clinical features and the histopathologic severity of rejection  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). There is widespread agreement that moderate or severe rejection (grade A3, A4) should be treated [
         <a href="#rid2">
          2,48
         </a>
         ]. The management of minimal or mild rejection (grade A1, A2) is more variable and often depends on the clinical setting and/or physician and patient preference and philosophy [
         <a href="#rid2">
          2
         </a>
         ]. In a large single center study (441 lung transplant recipients), there was no association between A1 rejection and subsequent development of CLAD, except in the subset who had higher concentrations of the chemokine CXCL9 in bronchoalveolar lavage (BAL) fluid [
         <a href="#rid54">
          54
         </a>
         ]. Additional research is needed to determine the clinical utility of BAL assessments for deciding which patients with minimal cellular rejection merit treatment. In a small observational study, patients with clinically silent and untreated A2 rejection were more likely to progress to higher grade rejection or develop obliterative bronchiolitis [
         <a href="#rid55">
          55
         </a>
         ]. Maintenance immunosuppression may be adjusted in some patients who do not meet criteria for treatment of acute rejection.
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunosuppression is usually not acutely increased in patients who have surveillance biopsies showing minimal rejection (A1), but no clinical signs or symptoms suggestive of rejection, and stable pulmonary function  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Practices are variable concerning the management of mild rejection on surveillance biopsies (A2) without clinical signs or symptoms of rejection or lung function decline  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). Some centers elect not to treat asymptomatic A2 rejection but will perform repeat surveillance bronchoscopy with biopsies in three to eight weeks. Our practice is to initiate treatment for A2 rejection even in the absence of symptoms or decline in pulmonary function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most centers, including ours, augment immunosuppression in patients with histologic evidence of minimal or mild rejection and a clinical syndrome suggestive of rejection.
        </p>
        <p>
        </p>
        <p>
         For symptomatic patients or those with airway secretions at bronchoscopy or radiographic abnormalities, empiric antibiotics are often initiated while waiting for culture results  (
         <a class="graphic graphic_figure graphicRef58770" href="/z/d/graphic/58770.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation", section on 'Pneumonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          High-dose glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal regimen for treating acute rejection has not been determined, so treatment choices are based on clinical experience. Typically, treatment is initiated with high dose parenteral glucocorticoids, such as intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (15 mg/kg, or 500 mg to 1 g intravenously per day) for three days [
         <a href="#rid2">
          2,48
         </a>
         ]. Dose adjustment is often considered in patients on azole antifungals, as
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         markedly prolongs the half-life of methylprednisolone  (
         <a class="graphic graphic_table graphicRef53228" href="/z/d/graphic/53228.html" rel="external">
          table 4
         </a>
         ). Pulse glucocorticoids can be done as an inpatient or outpatient, depending on patient symptoms, co-morbidities and available clinical infrastructure.
        </p>
        <p>
         Symptomatic improvement usually occurs over 24 to 48 hours in patients with symptoms of rejection, and the physiologic abnormalities begin to improve in the same time frame and return to baseline over several weeks. In a series of 85 patients with symptomatic acute lung transplant rejection, 47 (55 percent) responded to a glucocorticoid pulse [
         <a href="#rid56">
          56
         </a>
         ]. The strongest predictor of glucocorticoid response was onset a shorter time after transplantation.
        </p>
        <p>
         After high-dose intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , patients are returned to their baseline glucocorticoid dose or transitioned to a tapering course of oral glucocorticoids (starting at 0.5 to 1 mg/kg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ). Although specific regimens vary, the typical practice is to taper back to the baseline glucocorticoid dose over a several week period. Drug levels of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         need more frequent monitoring, as high-dose methylprednisolone has been associated with increased tacrolimus levels.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Follow-up bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical practice for follow-up after treatment of an episode of acute cellular rejection is not standardized. Centers that perform surveillance bronchoscopy to evaluate suspected acute rejection will also generally perform follow-up bronchoscopy. We typically perform follow-up bronchoscopy with bronchoalveolar lavage and transbronchial biopsies approximately three to four weeks after therapy (range of two to eight weeks).
        </p>
        <p>
         In a retrospective study of 242 bronchoscopies performed to assess response to treatment for acute rejection, a pathologic abnormality was noted in 62 percent. The clinical impression of whether the patient had responded to treatment was accurate in only one-half of cases [
         <a href="#rid57">
          57
         </a>
         ]. Decisions about therapy for persistent rejection seen on follow-up biopsies are typically made by criteria like those outlined above for the initial diagnosis. (See
         <a class="local">
          'Surveillance bronchoscopy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Persistent or refractory acute cellular rejection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy for persistent or refractory acute rejection is not well-established. Failure to respond to therapy for acute cellular rejection should prompt investigation for concomitant antibody-mediated rejection, if not already addressed. (See
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection", section on 'Diagnosis and differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Several approaches to refractory acute cellular rejection have been reported, and scientific data to support one over another are lacking. For persistent acute cellular rejection, our approach has been to treat a second time with intravenous glucocorticoids (eg, intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ) for three days. An alternative, for patients on a cyclosporine-based regimen, is to switch the maintenance immunosuppressive agent from
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         to
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid2">
          2,58-60
         </a>
         ]. (See
         <a class="local">
          'High-dose glucocorticoids'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'Calcineurin inhibitors'
         </a>
         .)
        </p>
        <p>
         If the subsequent biopsy shows a lower grade of rejection and the patient is getting better clinically, we often observe and repeat biopsies in three to four weeks. On the other hand, if evidence of rejection grade ≥A2 persists after two courses of glucocorticoids, we typically use antibody therapy for lymphodepletion (eg, antithymocyte globulin [ATG] or
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         ) and/or add a mechanistic target of rapamycin (previously mammalian target of rapamycin [mTOR]) inhibitor (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         ) [
         <a href="#rid17">
          17,48,61-63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'mTOR inhibitors'
         </a>
         .)
        </p>
        <p>
         If rejection appears severe or if the response to antibody therapy is incomplete, we also consider extracorporeal photopheresis (ECP) [
         <a href="#rid64">
          64-67
         </a>
         ] or pulse
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ]. ECP consists of infusion of ultraviolet-A irradiated autologous peripheral lymphocytes which have been collected by apheresis and incubated with 8-methoxypsoralen. The mechanism by which ECP decreases immune responses in transplant recipients is unclear but may involve enhancement of the number of peripheral regulatory T cells [
         <a href="#rid65">
          65,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">
          "Treatment of acute graft-versus-host disease", section on 'Extracorporeal photopheresis'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         , maintenance
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and total lymphoid irradiation have been used in the past for patients with recurrent rejection but are rarely used now [
         <a href="#rid70">
          70-72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5082262">
         <span class="h2">
          Adjusting maintenance immunosuppression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Re-evaluating and optimizing the maintenance immunosuppression regimen is appropriate in patients with acute or persistent rejection. This may include assessing blood levels of the immunosuppressive agents and the patient’s adherence to their immunosuppression regimen, as well as adjusting the regimen. The following potential changes depend on the individual patient’s maintenance regimen and the preferences of the local transplant team:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changing the maintenance immunosuppression from
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         to
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid59">
          59,60,73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'Calcineurin inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Changing the maintenance immunosuppression from
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         to a mycophenolic acid precursor. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'Nucleotide blocking agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adding a mTOR inhibitor (
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         ) to the maintenance regimen, if the time since lung transplantation is more than three months. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'mTOR inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Aerosolized
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         has been evaluated as an alternative therapy for acute lung transplant rejection [
         <a href="#rid74">
          74,75
         </a>
         ] and for prevention of allograft rejection [
         <a href="#rid76">
          76
         </a>
         ]. In a study of refractory acute rejection, eighteen patients who failed to improve following high-dose glucocorticoid and antilymphocyte globulin therapy were treated with aerosolized cyclosporine [
         <a href="#rid75">
          75
         </a>
         ]. Two patients were unable to tolerate treatment, but 14 had improvement in histologic rejection grade. A pilot study of aerosolized cyclosporine suggested a survival benefit but did not demonstrate a reduction in acute rejection [
         <a href="#rid76">
          76
         </a>
         ]; moreover, in preliminary results, a multi-center trial failed to demonstrate efficacy for aerosolized cyclosporine (CYCLIST trial) in prevention of acute rejection [
         <a href="#rid77">
          77
         </a>
         ]. Aerosolized cyclosporine is not commercially available and remains under investigation in clinical trials. (See
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation", section on 'Future directions'
         </a>
         .)
        </p>
        <p>
         Experience with the selective T cell co-stimulatory blocker,
         <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">
          belatacept
         </a>
         , is limited to retrospective reports of short term effectiveness for patients intolerant of calcineurin inhibitors, for prevention of acute cellular rejection or renal-sparing [
         <a href="#rid78">
          78,79
         </a>
         ]. However, recent reports suggest an increased risk for acute cellular rejection when belatacept is used without a calcineurin inhibitor [
         <a href="#rid80">
          80
         </a>
         ]. Further study will be necessary to define its role, if any, for treatment of refractory ACR and prevention of acute and chronic rejection.
        </p>
        <p class="headingAnchor" id="H622579866">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122278.html" rel="external">
          "Society guideline links: Lung transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15475603">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathophysiology
         </strong>
         – Acute cellular rejection is the predominant type of acute lung transplant rejection and is mediated by T lymphocytes directed against the donor major histocompatibility complexes (MHC), also known as human leukocyte antigens (HLA) in humans, or other antigens in the allograft. The risk of acute cellular rejection is greatest in the first few months after lung transplant and decreases with time. (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – Acute cellular rejection is a lymphocyte predominant inflammatory response. Vascular  (
         <a class="graphic graphic_picture graphicRef63730 graphicRef75560" href="/z/d/graphic/63730.html" rel="external">
          picture 1A-B
         </a>
         ) and airway  (
         <a class="graphic graphic_picture graphicRef77118 graphicRef52040" href="/z/d/graphic/77118.html" rel="external">
          picture 2A-B
         </a>
         ) components are described, either in isolation or simultaneously. The grading of acute cellular rejection is described in the table  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Patients with acute rejection may be asymptomatic, may have a decline in lung function, or may have low-grade fever, shortness of breath, or cough with or without sputum production. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance
         </strong>
         – Monitoring of asymptomatic patients usually includes spirometry and surveillance bronchoscopy with transbronchial biopsies of lower lobe subsegments to enable early diagnosis and treatment of acute rejection, and thus hopefully reduce the risk of chronic lung allograft dysfunction (CLAD). (See
         <a class="local">
          'Monitoring asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The evaluation of patients with suspected acute cellular rejection typically includes laboratory testing for evidence of infection, chest imaging, spirometry, and flexible bronchoscopy. During bronchoscopy, bronchoalveolar lavage and transbronchial biopsies (usually 6 to 10 biopsies to achieve at least five adequate samples) are obtained from areas of focal radiographic abnormality or from lower lobe subsegments. (See
         <a class="local">
          'Evaluation of symptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of acute lung transplant rejection is based on the presence of characteristic histopathologic changes on transbronchial lung biopsy specimens  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of declining allograft function occurring in the weeks to months after transplant includes infection, airway complications (eg, airway stenosis, malacia, or granulation tissue), chronic rejection (CLAD – bronchiolitis obliterans syndrome [BOS] or restrictive allograft syndrome [RAS]), volume overload, pleural effusion, thromboembolism, and recurrent primary disease. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – The decision to treat patients with histologic evidence of acute cellular lung allograft rejection is dependent upon the clinical setting and the severity of the rejection  (
         <a class="graphic graphic_table graphicRef61800" href="/z/d/graphic/61800.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Deciding when to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with moderate or severe rejection (grade A3, A4) without evidence of lung infection, we suggest treatment with intravenous glucocorticoids rather than other acute immunosuppressive regimens, such as antithymocyte globulin (ATG) or
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with mild rejection (grade A2) and patients with minimal rejection (grade A1) and symptoms of rejection or lung function decline, we suggest treatment with intravenous glucocorticoids after excluding lung infection rather than early repeat surveillance transbronchial biopsy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Conversely, patients with minimal acute cellular rejection (grade A1) who have no symptoms of rejection and no lung function decline are not typically treated with additional immunosuppression but are instead monitored clinically and with continued standard transbronchial biopsy surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For initial treatment of acute cellular rejection, we typically use intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (15 mg/kg, or 0.5 to 1 gram IV per day) for three days. After clinical response, patients are transitioned to oral glucocorticoids, typically 0.5 to 1 mg/kg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         /day, which is tapered to the patient’s baseline dose over several weeks. (See
         <a class="local">
          'High-dose glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up surveillance
         </strong>
         – Guidelines for follow-up bronchoscopy after treatment of an episode of acute cellular rejection are not standardized. We typically perform a follow-up bronchoscopy approximately three to four weeks after treatment (range of two to eight weeks). (See
         <a class="local">
          'Follow-up bronchoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional treatment for persistent or refractory disease
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with persistent acute cellular rejection, we suggest a second course of intravenous glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , 0.5 to 1 gram IV daily for three days) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). An alternative or adjunctive therapy, for occasional patients using a cyclosporine-based regimen, is to change the maintenance calcineurin inhibitor from
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         to
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         . (See
         <a class="local">
          'Persistent or refractory acute cellular rejection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If evidence of acute cellular rejection persists on follow-up biopsies after two courses of glucocorticoids, an alternate immunosuppressive agent, such as ATG or
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         , is usually administered for acute treatment. (See
         <a class="local">
          'Persistent or refractory acute cellular rejection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4661.html" rel="external">
          "Induction immunosuppression following lung transplantation", section on 'Induction agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The maintenance immunosuppression regimen is usually adjusted in patients with recurrent acute or persistent evidence of rejection on follow-up biopsies. Potential changes include substituting
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         for
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         for
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or adding a mammalian target of rapamycin (mTOR) inhibitor. (See
         <a class="local">
          'Adjusting maintenance immunosuppression'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">
          "Maintenance immunosuppression following lung transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2997864">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges John Reilly, Jr., MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinu T, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral processes. Clin Chest Med 2011; 32:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angaswamy N, Tiriveedhi V, Sarma NJ, et al. Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol 2013; 74:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verleden SE, Todd JL, Sato M, et al. Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study. Am J Transplant 2015; 15:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakinala MM, Trulock EP. Acute allograft rejection after lung transplantation: diagnosis and therapy. Chest Surg Clin N Am 2003; 13:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adoumie R, Serrick C, Giaid A, Shennib H. Early cellular events in the lung allograft. Ann Thorac Surg 1992; 54:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach FH, Sachs DH. Current concepts: immunology. Transplantation immunology. N Engl J Med 1987; 317:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krensky AM, Weiss A, Crabtree G, et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton CM, Iversen M, Scheike T, et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008; 27:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Berry GJ, Brunt EM, et al. A working formulation of the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung rejection study group. J Heart Lung Transplant 1990; 9:S93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todd JL, Neely ML, Kopetskie H, et al. Risk Factors for Acute Rejection in the First Year after Lung Transplant. A Multicenter Study. Am J Respir Crit Care Med 2020; 202:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman LL, Weinberg AD, McGregor C, et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girnita DM, Webber SA, Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med 2008; 28:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005; 14:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colobran R, Casamitjana N, Roman A, et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun 2009; 10:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005; 171:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowery EM, Bemiss B, Cascino T, et al. Low vitamin D levels are associated with increased rejection and infections after lung transplantation. J Heart Lung Transplant 2012; 31:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton CM, Iversen M, Scheike T, et al. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008; 85:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins PM, Aboyoun CL, Chhajed PN, et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002; 21:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Vito Dabbs A, Hoffman LA, Iacono AT, et al. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung 2004; 33:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Muylem A, Mélot C, Antoine M, et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997; 52:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otulana BA, Higenbottam T, Scott J, et al. Lung function associated with histologically diagnosed acute lung rejection and pulmonary infection in heart-lung transplant patients. Am Rev Respir Dis 1990; 142:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millet B, Higenbottam TW, Flower CD, et al. The radiographic appearances of infection and acute rejection of the lung after heart-lung transplantation. Am Rev Respir Dis 1989; 140:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gotway MB, Dawn SK, Sellami D, et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology 2001; 221:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinu T, Koutsokera A, Benden C, et al. International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation. J Heart Lung Transplant 2020; 39:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiroke AH, Bewig B, Haverich A. Bronchoalveolar lavage in lung transplantation. State of the art. Clin Transplant 1999; 13:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clelland C, Higenbottam T, Stewart S, et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis 1993; 147:1386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasegawa T, Iacono AT, Yousem SA. The anatomic distribution of acute cellular rejection in the allograft lung. Ann Thorac Surg 2000; 69:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tazelaar HD, Nilsson FN, Rinaldi M, et al. The sensitivity of transbronchial biopsy for the diagnosis of acute lung rejection. J Thorac Cardiovasc Surg 1993; 105:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faro A, Visner G. The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplant 2004; 8:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starnes VA, Barr ML, Cohen RG. Lobar transplantation. Indications, technique, and outcome. J Thorac Cardiovasc Surg 1994; 108:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008; 27:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine VG, Gupta MR, Weill D, et al. Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation. J Heart Lung Transplant 2009; 28:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008; 177:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morlion B, Knoop C, Paiva M, Estenne M. Internet-based home monitoring of pulmonary function after lung transplantation. Am J Respir Crit Care Med 2002; 165:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otulana BA, Higenbottam T, Ferrari L, et al. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation. Chest 1990; 97:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjørtuft O, Johansen B, Boe J, et al. Daily home spirometry facilitates early detection of rejection in single lung transplant recipients with emphysema. Eur Respir J 1993; 6:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker FS, Martinez FJ, Brunsting LA, et al. Limitations of spirometry in detecting rejection after single-lung transplantation. Am J Respir Crit Care Med 1994; 150:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson KS, West AJ. Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: Daily home spirometry versus standard pulmonary function testing. Can J Respir Ther 2014; 50:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine SM, Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest 2004; 125:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glanville AR. Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med 2010; 31:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandrini A, Glanville AR. The controversial role of surveillance bronchoscopy after lung transplantation. Curr Opin Organ Transplant 2009; 14:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dransfield MT, Garver RI, Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. J Heart Lung Transplant 2004; 23:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izbicki G, Bairey O, Shitrit D, et al. Increased thromboembolic events after lung transplantation. Chest 2006; 129:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad S, Shlobin OA, Nathan SD. Pulmonary complications of lung transplantation. Chest 2011; 139:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shino MY, Weigt SS, Li N, et al. The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction. Am J Transplant 2018; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yousem SA. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol 1996; 27:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuehner T, Simon A, Dierich M, et al. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation. Respir Med 2009; 103:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995; 152:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meiser BM, Uberfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shennib H, Massard G, Reynaud M, Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant 1994; 13:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant 2007; 7:2802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudzik KN, Moore CA, Sacha LM, et al. Rabbit Antithymocyte Globulin for Treatment of Corticosteroid Refractory Acute Cellular Rejection After Lung Transplantation. Transplantation 2023; 107:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008; 86:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise BV, King KE, Rook AH, Mogayzel PJ Jr. Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient. Prog Transplant 2003; 13:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002; 26:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naik C, Moore C, Pipeling M, et al. Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation. Transplant Direct 2018; 4:e350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meloni F, Cascina A, Miserere S, et al. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cahill BC, O'Rourke MK, Strasburg KA, et al. Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant 1996; 15:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross HJ, Gullestad L, Pak J, et al. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant 1997; 16:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest 1996; 109:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenan RJ, Zeevi A, Iacono AT, et al. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 1995; 118:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenan RJ, Iacono A, Dauber JH, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997; 113:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354:141.
          </a>
         </li>
         <li class="breakAll">
          Aerosol Cyclosporine for Prevention of Lung Rejection, NCT00268515. www.clinicaltrials.gov (Accessed on January 28, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timofte I, Terrin M, Barr E, et al. Belatacept for renal rescue in lung transplant patients. Transpl Int 2016; 29:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iasella CJ, Winstead RJ, Moore CA, et al. Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. Transplantation 2018; 102:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brugière O, Vallée A, Raimbourg Q, et al. Conversion to belatacept after lung transplantation: Report of 10 cases. PLoS One 2023; 18:e0281492.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4655 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19131531" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acute rejection and humoral sensitization in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21511091" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute allograft rejection: cellular and humoral processes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26454740" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12133982" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23876679" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25940517" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773319" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The role of innate immunity in acute allograft rejection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13678311" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute allograft rejection after lung transplantation: diagnosis and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1449289" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early cellular events in the lung allograft.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3302709" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Current concepts: immunology. Transplantation immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2405272" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : T-lymphocyte-antigen interactions in transplant rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18926405" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A working formulation of the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung rejection study group
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8820078" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18096473" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32379979" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk Factors for Acute Rejection in the First Year after Lung Transplant. A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9620914" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19028261" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15814280" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19148142" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640363" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Innate immunity influences long-term outcomes after human lung transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22975097" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21962018" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22386448" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low vitamin D levels are associated with increased rejection and infections after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347533" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12398870" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15597291" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9246138" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2382896" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lung function associated with histologically diagnosed acute lung rejection and pulmonary infection in heart-lung transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2502057" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The radiographic appearances of infection and acute rejection of the lung after heart-lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568342" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32773322" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10202611" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bronchoalveolar lavage in lung transplantation. State of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8503549" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10881836" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The anatomic distribution of acute cellular rejection in the allograft lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8469001" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The sensitivity of transbronchial biopsy for the diagnosis of acute lung rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1327662" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15265155" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8078333" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lobar transplantation. Indications, technique, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18971092" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Surveillance bronchoscopy in lung transplant recipients: risk versus benefit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19134525" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Single-institution study evaluating the utility of surveillance bronchoscopy after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263803" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11874816" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Internet-based home monitoring of pulmonary function after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2298060" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8390943" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Daily home spirometry facilitates early detection of rejection in single lung transplant recipients with emphysema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8025743" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Limitations of spirometry in detecting rejection after single-lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26078605" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: Daily home spirometry versus standard pulmonary function testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078729" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A survey of clinical practice of lung transplantation in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20354933" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Bronchoscopic monitoring after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620869" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The controversial role of surveillance bronchoscopy after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734135" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16478860" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Increased thromboembolic events after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21285054" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pulmonary complications of lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28637080" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8600042" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19398195" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8520773" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9286771" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11927219" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15052212" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8061029" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17924993" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37143198" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Rabbit Antithymocyte Globulin for Treatment of Corticosteroid Refractory Acute Cellular Rejection After Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11233043" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Extracorporeal photopheresis for the treatment of lung allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19077900" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12688651" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12126206" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29796421" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17275508" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8956122" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Methotrexate for lung transplant recipients with steroid-resistant acute rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9059929" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8625664" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363689" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7638755" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9040628" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16407509" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A randomized trial of inhaled cyclosporine in lung-transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16407509" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A randomized trial of inhaled cyclosporine in lung-transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26678245" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Belatacept for renal rescue in lung transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28691954" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36920935" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Conversion to belatacept after lung transplantation: Report of 10 cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
